Potential Payoffs Spuring Big Board Biotechs Print E-mail
By Staff and Wire Reports   
Tuesday, 12 August 2014 02:59
Speculators were pushing certain big board biotechs higher as they placed their bets on potential future payoffs.
Read more...
 
Expert Briefing: New Immunotherapy Technologies Provide Hope In Breast and Ovarian Cancer Print E-mail
By M.E.Garza   
Wednesday, 23 July 2014 04:20
icon_expertbriefingLast month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the company’s scientific advisory board.
Read more...
 
Sage Therapeutics: Hot IPO, Great Start in CNS Print E-mail
By Brian Wilson   
Sunday, 20 July 2014 22:44
Last week, we saw a very successful IPO for Sage Therapeutics (SAGE) - a company that focuses on treating rare diseases that affect the central nervous system. Although the company is still in the relatively early stages of the development cycle, the company has already attained an enterprise valuation of $696 M after investors brought the stock 67% higher last Friday. 
Read more...
 
Don’t Buy Into In Prana’s Data Mining Strategy Print E-mail
By Brian Wilson   
Thursday, 17 July 2014 11:23
Despite the continuing pain in the biotech sector, Prana (PRAN) is up 15% at time of writing based on a press release issued yesterday about the company’s efforts to revive the failed Alzheimer’s drug PBT2.  
Read more...
 
Bigger Moves Coming For Exelixis Print E-mail
By Brian Wilson   
Tuesday, 15 July 2014 08:05
It took a while for investor sentiment in Exelixis (EXEL) to recover after the company released less-than-stellar interim results for its Phase III Metastatic Castration-Resistant Prostate Cancer (mCRPC) trial for cabozantinib (COMET-1) back in March, but it appears that positive news from the cobimetinib program is helping to lighten the mood a bit.
Read more...
 
Q&A with Zami Aberman, Pluristem Therapeutics Print E-mail
By BioMedReports.Com   
Monday, 14 July 2014 17:17
Zami Aberman, CEO of Haifa-based Pluristem Therapeutics, a leading developer of placenta-based cell therapies, recently announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC).
Read more...
 
Insiders Are Dumping Questcor – Here’s Why Print E-mail
By Brian Wilson   
Monday, 14 July 2014 08:16
After a 70% rally since the start of the year, it’s time to reevaluate the valuation of Questcor Pharma (QCOR) and the reasoning behind the sale of ~1.3 million shares by insiders since January 1st.
Read more...
 
Investor Panic Sends Sarepta Down Sharply Print E-mail
By Brian Wilson   
Thursday, 10 July 2014 09:12
Earlier this morning, Sarepta Therapeutics (NASDAQ: SRPT) announced long-term outcomes (through 144 weeks) from the Phase IIb study of the drug eteplirsen for Duchenne Muscular Dystrophy. This 12 patient trial, which was initiated in February 2012, has been the primary driver of Sarepta’s valuation for roughly three years.
Read more...
 
Will New Trials Renew Enthusiasm In La Jolla Pharma? Print E-mail
By Brian Wilson   
Wednesday, 09 July 2014 07:44
La Jolla Pharma (LJPC) is a small pharmaceutical company that focuses on galectin inhibition, iron absorption deficiencies, and on hypotension. 
Read more...
 
Tekmira Selloff Could Be Exaggerated Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 07 July 2014 08:30
On July 3rd of last week, Tekmira (TKMR) fell over 15% after the FDA put a clinical hold on the company’s Phase I trial for TKM-Ebola – an early-stage RNAi therapeutic for the Ebola virus.
Read more...
 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 11 of 56

Newsletter